Friday 22 Jun, 2018 03:20 AM
Site map | Locate Us | Login
   Lakshmi Vilas Bank vaults on fund raising plan     Himachal Futuristic Communications Ltd leads losers in 'A' group    Hindusthan National Glass & Industries Ltd leads losers in 'B' group    Volumes soar at Thyrocare Technologies Ltd counter    Hindustan Copper Ltd drops for fifth straight session    Punjab National Bank slips for fifth straight session    Tree House Education & Accessories Ltd leads gainers in 'B' group    AXISCADES Engg gains after forming JV with Assystem     Vakrangee Ltd leads gainers in 'A' group    InterGlobe Aviation advances after clarification    Volumes jump at Adani Ports & Special Economic Zone Ltd counter    Gayatri Projects drops after project cancellation    Majesco sizzles after new order win    Bhel gains after new order win    Interglobe Aviation Ltd leads losers in 'A' group 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Alembic Pharma spurts after USFDA nod for Doxycycline Hyclate capsules
14-Jun-18   11:11 Hrs IST

The announcement was made during trading hours today, 14 June 2018.

Meanwhile, the S&P BSE Sensex was down 197.41 points, or 0.55% to 35,541.75.

On the BSE, 34,000 shares were traded in the counter so far compared with average daily volumes of 20,000 shares in the past two weeks. The stock had hit a high of Rs 529.90 and a low of Rs 478.05 so far during the day. The stock hit a 52-week high of Rs 588 on 15 February 2018. The stock hit a 52-week low of Rs 412.40 on 24 May 2018.

Alembic Pharmaceuticals announced that it has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Hyclate capsules USP, 50 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vibramycin capsules, 50 mg and 100 mg, of Pfizer Inc.

Doxycycline is indicated for a wide variety of bacterial infections including those caused by several gram-negative as well as gram-positive microorganisms. Doxycycline is also indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (<4 months) to areas with chloroquine and/or pyrimethaminesulfadoxine resistant strains. Doxycycline may be a useful adjunctive therapy in severe acne and in acute intestinal amebiasis.

Doxycycline Hyclate capsules USP, 50 mg and 100 mg, have an estimated market size of $80 million for twelve months ending December 2017 according to IQVIA. Alembic now has a total of 73 ANDA approvals (65 final approvals and 8 tentative approvals) from USFDA.

On a consolidated basis, net profit of Alembic Pharmaceuticals rose 0.81% to Rs 93.79 crore on 15.10% rise in net sales to Rs 853.31 crore in Q4 March 2018 over Q4 March 2017.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.G Anand , anand@ssplwealth.com
Hit Count : 8860572
SEBI Regn.Nos : NSE Cash : INB231122137  |  NSE F&O  : INF231122137  |  BSE Cash : INB011122133  |  BSE F&O : INF011122133  |  NSE CD : INE231122137  
MCX-SX CD :INE261122137   |  USE CD : INE271122132  |  CDSL : IN-DP-CSDL-262-2016/, AMFI Regn.No : 2662, FMC Regn. No : MCX / TCM / CORP / 0186 | MCX :12815 * 
Member IDs : NSE :11221  |  BSE :6292  |  USE :11221  |  MCX-SX :25500  |  CDSL :12045000   ( * through associate company SSPL commodities)
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. Saravana Stocks Pvt. Ltd